Dehydroepiandrosterone

3ß-hydroxy-5-androsten-17-one
CAS number 53-43-0	ATC code A14AA07
Chemical formula	C19H28O2
Molecular weight	288.43
Bioavailability	?%
Metabolism	Hepatic
Elimination half-life	12 hours
Excretion	Urinary:?%
Pregnancy category	?
Legal status	Commercially available (US)
Routes of administration	Oral
Melting point	146–151°C
Specific rotation *D

Dehydroepiandrosterone (DHEA), is a natural steroid hormone produced from cholesterol by the adrenal glands found atop of the kidneys in the human body. DHEA is also produced in the gonads, adipose tissue and the brain. DHEA is structurally similar to, and is a precursor of, androstenedione, testosterone and estrogen. It is the most abundant hormone in the human body. Synonymes for Dehydroepiandrosterone are: Dehydroisoandrosterone; 3beta-Hydroxy-5-androsten-17-one; 3beta-Hydroxyandrost-5-en-17-one; Androstenol; Androstenolone; Dehydroisoandrosterone; Hydroxyandrost-5-en-17-one; Prasterone; trans-Dehydroandrosterone. Brand names for DHEA include Prastera® and Fidelin®.

DHEA-DHEAS

---

Dehydroepiandrosterone sulfate (DHEAS) is the sulfated version of DHEA, - this conversion is reversibly catalyzed by sulfotransferase (SULT2A1) primarily in the adrenals, the liver, and small intestines. In blood, most DHEA is found as DHEAS with levels that are about 300 times higher than free DHEA. Orally ingested DHEA is converted to its sulfate when passing through intestines and liver. While DHEA levels reach their peak in the early morning hours, DHEAS levels show no diurnal variation. DHEAS is biologically active only after its sulfate group has been split and it becomes DHEA again.

More on [ Dehydroepiandrosterone ]

CFDA: FDA Latest Computer Systems Warning Letters

WL Issued to Oncology Tech, LLP
FDA Fri, 27 Jun 2008 00:00:00 -0400
FDA Warning Letter Issued to Oncology Tech, LLP on 27 Jun 2008 by Dallas District Office
WL Issued to Mostel, Edward, M.D.
FDA Fri, 16 May 2008 00:00:00 -0400
FDA Warning Letter Issued to Mostel, Edward, M.D. on 16 May 2008 by Center for Drug Evaluation and Research
WL Issued to Merck & Company, Inc.
FDA Mon, 28 Apr 2008 00:00:00 -0400
FDA Warning Letter Issued to Merck & Company, Inc. on 28 Apr 2008 by Office of Enforcement
WL Issued to Blood Center of New Jersey
FDA Tue, 15 Apr 2008 00:00:00 -0400
FDA Warning Letter Issued to Blood Center of New Jersey on 15 Apr 2008 by New Jersey District Office
WL Issued to Asfora, Wilson T. M.D.
FDA Mon, 07 Apr 2008 00:00:00 -0400
FDA Warning Letter Issued to Asfora, Wilson T. M.D. on 07 Apr 2008 by Center for Devices and Radiological Health
WL Issued to Philips Medical Systems, Inc
FDA Tue, 01 Apr 2008 00:00:00 -0400
FDA Warning Letter Issued to Philips Medical Systems, Inc on 01 Apr 2008 by Cincinnati District Office

CFDA: FDA Latest Drug GCP Warning Letters

WL Issued to Gardiziola, Gregory, D.O.
FDA Wed, 03 Sep 2008 00:00:00 -0400
FDA Warning Letter Issued to Gardiziola, Gregory, D.O. on 03 Sep 2008 by Center for Drug Evaluation and Research
WL Issued to Hamilton Medical Center
FDA Tue, 02 Sep 2008 00:00:00 -0400
FDA Warning Letter Issued to Hamilton Medical Center on 02 Sep 2008 by Center for Devices and Radiological Health
WL Issued to Ziran, Bruce H., MD
FDA Wed, 27 Aug 2008 00:00:00 -0400
FDA Warning Letter Issued to Ziran, Bruce H., MD on 27 Aug 2008 by Center for Devices and Radiological Health
WL Issued to Hospital Municipal de San Juan
FDA Fri, 15 Aug 2008 00:00:00 -0400
FDA Warning Letter Issued to Hospital Municipal de San Juan on 15 Aug 2008 by Center for Drug Evaluation and Research
WL Issued to Valley Baptist Medical Center IRB
FDA Mon, 11 Aug 2008 00:00:00 -0400
FDA Warning Letter Issued to Valley Baptist Medical Center IRB on 11 Aug 2008 by Center for Devices and Radiological Health
WL Issued to Husain, Mustafa M, M.D.
FDA Wed, 23 Jul 2008 00:00:00 -0400
FDA Warning Letter Issued to Husain, Mustafa M, M.D. on 23 Jul 2008 by Center for Devices and Radiological Health

Subscribe to Drugs_and_Medications RSS feed